tbuckley/cabot-search huggingface dataset:
885. VEGF Enhances Bone Formation and Bone Healing Elicited by Transduced Muscle-Derived Stem Cells Expressing Human BMP2
Authors: Sanjay Kumar, Gandham Mahendra, Selvarangan Ponnazhagan
Journal: Molecular Therapy (2004)

The strength and integrity of metabolically active bone depends on the balanced activity of two different cell types, namely osteoclasts, which resorbs the bone and osteoblasts which form new bone. Loss of this homeostasis results in a decrease in bone mass, leading to defects in mineralization of bone, resulting in osteopenic conditions including osteoporosis. Ex vivo gene therapy for osteoporosis is a rational alternative to the existing therapies and the potential of rAAV with long-term expression capability should provide greater benefit in this regard. A potential osteoporosis gene therapy is by using an ex vivo approach with gene modified mesenchymal stem cells (MSC) expressing osteogenic agents, which provide a local supply of precursor cells and a supraphysiological dose of osteoinductive molecules, which may promote bone formation. Towards achieving this goal with rAAV, capable of long term expression, we determined osteoprogenitor-specific expression of rAAV-transduced bone marrow stromal cells in vitro. rAAV vectors containing luciferase gene under the control of CMV, alkaline phosphatase, cbfa-1, collagen type-I, osteopontin and osteocalcin promoters were transduced to mouse MSC in replicates in vitro. Following transduction, cells were either maintained as undifferentiated cultures or induced to undergo early differentiation by the addition of 10 mM β-glycerophosphate, 50 μM ascorbic acid and 100 ng/ml recombinant BMP-2. Luciferase activity was determined at different time points as a measure of promoter activation. Results of these studies indicated that there was no significant difference in CMV activity between undifferentiated and BMP-2 differentiated MSC at different time points. However, luciferase activity from alkaline phosphatase, cbfa-1, collagen type-I, osteopontin and osteocalcin promoters in BMP-2 induced MSC cultures indicated increase in transgene expression over time, whereas no significant increase was observed in undifferentiated cultures. Among the bone-specific promoters tested, expression of collagen type-I and cbfa-1 promoters were more pronounced during early differentiation (48 hours) compared to osteocalcin, alkaline phophatase and osteopontin promoters. Northern blot analysis was done with RNA obtained from BMP-2 differentiated MSC at different time points to confirm BMP-2 induced osteoblastic changes in cultured and differentiated MSC. Results of these studies indicate that by using bone specific promoters that are active during early differentiation of MSC, lineage-restricted expression of therapeutic proteins is possible to enhance osteoblast production for increased bone mass.
Involvement of inhibitory NKRs in the survival of a subset of memory-phenotype CD8+ T cells
Authors: Sophie Ugolini, Christophe Arpin, Nicolas Anfossi, Thierry Walzer, Anna Cambiaggi, Reinhold Förster, Martin Lipp, René E. M. Toes, Cornelius J. Melief, Jacqueline Marvel, Eric Vivier
Journal: Nature Immunology (2001)
Mammary Lesions and Viral Agents in the Milk of NZB Mice
Authors: K. H. Hollmann, J. M. Verley, Nurul H. Sarkar, Jesse Charney, Dan H. Moore
Journal: JNCI Journal of the National Cancer Institute (1972)

Mammary Lesions and Viral Agents in the Milk of NZB Mice Get access K. H. Hollmann, K. H. Hollmann 1Laboratoire de Cytopathologie, Hôpital Broussais (Collège de France), Paris, France Search for other works by this author on: Oxford Academic PubMed Google Scholar J. M. Verley, J. M. Verley 1Laboratoire de Cytopathologie, Hôpital Broussais (Collège de France), Paris, France Search for other works by this author on: Oxford Academic PubMed Google Scholar Nurul H. Sarkar, Nurul H. Sarkar 2Institute for Medical Research, Camden, New Jersey 08103 Search for other works by this author on: Oxford Academic PubMed Google Scholar Jesse Charney, Jesse Charney 2Institute for Medical Research, Camden, New Jersey 08103 Search for other works by this author on: Oxford Academic PubMed Google Scholar Dan H. Moore Dan H. Moore 2Institute for Medical Research, Camden, New Jersey 08103 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 48, Issue 4, April 1972, Page 1243, https://doi.org/10.1093/jnci/48.4.1243 Published: 01 April 1972
Minorities in Clinical Trials
Authors: Tracy Hampton
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Letter by Stöllberger and Finsterer Regarding Article, “Reversible De Novo Left Ventricular Trabeculations in Pregnant Women: Implications for the Diagnosis of Left Ventricular Noncompaction in Low-Risk Populations”
Authors: Claudia Stöllberger, Josef Finsterer
Journal: Circulation (2015)

With interest we read the article by Gati et al 1 who detected the development of left ventricular hypertrabeculation/noncompaction (LVHT) in 25% of pregnant women by serial echocardiographies, which resolved in 73% postpartum.These findings challenge the hypothesis that LVHT is attributable to a disturbed compaction process of the embryonic heart.Acquired LVHT has previously been reported in nonathletes and nonpregnant patients, the majority of whom experienced a neuromuscular disorder. 2,3hus, it would be of interest if any of the women who developed LVHT experienced a neuromuscular disorder or if neuromuscular disorders were found in their families.Although the study suggests that LVHT can be acquired, it has frequently been associated with genetic disorders and found in other family members.Were relatives of the pregnant women with LVHT systematically investigated for LVHT to completely rule out a hereditary cause?How many of the family members had a history of stroke, embolism, heart failure, syncope, or sudden cardiac death?In how many of the pregnant females was an echocardiographic investigation before pregnancy available?Were these previous investigations systematically screened for LVHT?The authors hypothesize that LVHT occurs in response to physiological changes in pregnancy.Because anemia is a frequent finding in pregnancy, it would be interesting to know the prevalence of anemia in women with and without LVHT.Five of the 6 women with persistent LVHT in the postpartum period were aged ≥34 years.Thus, it would be interesting to calculate whether development or persistence of LVHT increased with age.Did the outcomes of pregnancy and prevalence of problems during delivery differ between women with and without LVHT?Was LVHT or any other cardiac or noncardiac abnormality diagnosed in their babies?Lactation and oxytocin levels influence the cardiovascular system. 4Was the regression or persistence of LVHT dependent on breast-feeding in the postpartum period?It should be clarified at which time in the first trimester the echocardiography was carried out and whether the number of trabeculations at the first echocardiography was associated with the development of LVHT during pregnancy.
Abstract 3561: Whole transcriptome analysis of testicular germ cell tumors
Authors: Lovorka Degoricija, Kathy Y. Lee, Sunali Patel, Shirley Chu, Ad J.M. Gillis, Martin Rijlaarsdam, Lambert C.J. Dorssers, Leendert Looijenga
Journal: Cancer Research (2014)

Abstract Next generation sequencing of the whole transcriptome enables high resolution measurement of gene expression activity in different tissue and cell types. This methodology provides an in depth study of known transcripts and depending on the data analysis, allows identification of additional transcript types such as transcript variants, fusion transcripts, and small and long ncRNAs. In this study we performed RNA-Seq using the Ion Torrent sequencing platform to compare the expression profile of testicular germ cell tumors (seminoma type, n=3) and normal testis (n=3). Using Partek Flow and Star or TopHat aligners, we aligned the reads to the human genome and mapped sequences to the RefSeq database. We identified a large number of genes that were up and down regulated with high degree of significance p&amp;lt;0.01, &amp;gt;2X FC). These included genes related to testicular tissue type, stem cell pleuripotency (NANOG; POU5F1) and proliferation (KRAS, CCND2). In addition, a number of differentially expressed noncoding RNAs were identified (SNORD12B, XIST). The method was validated on a small set of genes (&amp;gt;20) using qPCR (TaqMan Assays). We used the Open Array platform to quantitatively screen a larger number of differentially expressed genes (224) across a number of different testicular germ cell tumor types (non-seminoma). Citation Format: Lovorka Degoricija, Kathy Y. Lee, Sunali Patel, Shirley Chu, Ad J.M. Gillis, Martin Rijlaarsdam, Lambert C.J. Dorssers, Leendert Looijenga. Whole transcriptome analysis of testicular germ cell tumors. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3561. doi:10.1158/1538-7445.AM2014-3561
Rotavirus Vaccine a Boon to ChildrenWoman Physician-Politician Is New Head of WHOHIV/AIDS Care Calls for Reallocation of ResourcesRotavirus Vaccine a Boon to ChildrenWoman Physician-Politician Is New Head of WHOHIV/AIDS Care Calls for Reallocation of Resources
Authors: C Marwick
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mechanistic evaluation of the combination effect of anti-VEGF and chemotherapy
Authors: Ian Kasman, Anil Bagri, Judy Mak, Franklin Peale, Rick Carano, Jed Ross, Leanne Berry, Young Shin, Patrick Rudewicz, Cary Austin, Ronald Ferrando, Sarajane Ross, Lisa Crocker, Nicolas Van Bruggen, Harriet Pais, Kurt Scudder, Beth Hollister, Greg Plowman
Journal: Cancer Research (2008)

2494  	Bevacizumab (AvastinTM) a monoclonal Anti-VEGF antibody, is currently approved in a number of oncologic indications in combination with standard-of-care chemotherapy. However, the mechanism of action of this combined efficacy is not well understood. It has been proposed that anti-VEGF mediated vascular normalization may result in increased delivery of chemotherapy to tumors. To address this and other potential mechanisms of combination activity, a murine and human cross-reactive anti-VEGF mAb (B20.4.1) was administered to multiple tumor xenografts in combination with a number of standard chemotherapeutics. Significant additive activity was commonly seen between B20.4.1 and chemotherapy.  	We subsequently performed additional analysis on a subset of the models in order to elucidate the potential mechanisms responsible for this additive effect, including increased delivery of the chemotherapeutic to tumor cells, enhanced tumor cell killing, changes in drug activation or metabolism and increased vascular damage. Overall changes in tumor morphology and physiology were examined histologically, and by micro-CT, and suggest that combination effects are seen as early as three days after initiation of treatment and persist long-term. Furthermore, drug activation or metabolism did not significantly change with anti-VEGF treatment. More subtle and specific analysis, such as tumor or endothelial specific proliferation, apoptosis and DNA damage, that may play a crucial role in the treatment outcome, was performed utilizing multi-channel immunofluorescence microscopy. In order to tease out the early mechanistic changes responsible for the additive downstream effects observed, we performed detailed analyses at early time points following drug administration. We observed that chemotherapy induced vascular damage sensitized tumor vasculature to the effects of anti-VEGF treatment. This, along with other published data, suggests that multiple mechanisms are likely to contribute to the additive efficacy seen with anti-VEGF in combination with cytotoxic drugs. These results are likely to have broad implications for the utility of anti-angiogenic therapies alone and in combination with chemotherapeutic agents.
Abstract B11: Stromal response to prostate cancer therapeutics
Authors: Dominique Nicole Gales, Khalda Fadlalla, Upender Manne, Clayton Yates, Temesgen Samuel
Journal: Clinical Cancer Research (2015)

Abstract Docetaxel (D) is a clinically used front-line chemotherapeutic agent for castration resistant advanced prostate cancer (Pca). However, its long-term benefits are limited, with most patients eventually progressing because of inherent or acquired drug resistance. The treatment of advanced Pca is a significant challenge and there are no effective treatments that stably suppress the disease. The mechanisms behind the resistance to Docetaxel are not fully understood. It is well accepted that tumor microenvironment is essential for tumor cells survival, cancer progression and metastasis. However, the mechanisms by which tumor cells interact with their surrounding at different stages of cancer development or during chemotherapy are largely unidentified. The central goal is to identify the cellular and biochemical responses of stromal cells in tumor microenvironment with which prostate cancer cells interact. Specifically, the interaction of prostate cancer cells with stromal cells of the prostate or the bone microenvironment in the presence of clinically used cancer therapeutics will be examined. Key regulators of these interactions will also be identified. Such regulators include cytokines, growth factors, proteins, and their receptors. By identifying these regulators and their contribution to tumor drug response, novel therapeutics targeted to the microenvironment can be developed. Therefore, we hypothesize that the response of prostate stromal cells exposed to chemotherapeutic agents could modify drug response or therapeutic outcome of prostate cancer. Cellular proliferation was analyzed by MTT assay. The IC50 of Docetaxel for WPMY-1 (normal stromal), LNCaP (androgen dependent), DU-145 (androgen independent), and HS27A (bone stromal) showed inhibitory effects between 2-10nM. Cell cycle profiles were assessed by flow cytometry. The analysis showed that Docetaxel (2-50nM) induced prominent G2-M arrest in prostate and stromal cells within 24 hours. Gene expression profiling of prostate cancer and stromal cells lines were evaluated. To obtain the expression profiles, we conducted a human cytokines and chemokines array, which consisted of 84 specific genes. Analysis of the prostate cancer and stromal cells treated with Docetaxel revealed differential expression patterns. These results suggest Docetaxel exhibits strong anti-proliferative effects and analysis of the gene array suggest regulation of genes associated with, cell growth, survival, proliferation, metastasis, angiogenesis, and apoptosis. Note: This abstract was not presented at the conference. Citation Format: Dominique Nicole Gales, Khalda Fadlalla, Upender Manne, Clayton Yates, Temesgen Samuel. Stromal response to prostate cancer therapeutics. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Drug Sensitivity and Resistance: Improving Cancer Therapy; Jun 18-21, 2014; Orlando, FL. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(4 Suppl): Abstract nr B11.
Global Road Safety Crisis Remedy Sought
Authors: Thomas B Cole
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract P191: Carotid Intima-Media Thickness is Associated with Systolic Blood Pressure, Body-Mass Index and LDL Cholesterol in Low-Risk Individuals. A Cross-Sectional Analysis of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil).
Authors: Itamar S Santos, Márcio S Bittencourt, Ilka R Oliveira, Angelita G Souza, Danilo P Meireles, Tatjana Rundek, Murilo Foppa, Daniel C Bezerra, Leonard H Roelke, Isabela M Benseñor, Paulo A Lotufo
Journal: Circulation (2015)

Introduction: Carotid intima-media thickness (cIMT) is a noninvasive measurement of early atherosclerosis by ultrasound. Determinants of cIMT in individuals without classical cardiovascular (CV) risk factors are poorly studied. Hypothesis: We assessed the hypothesis that systolic blood pressure (SBP), body-mass index (BMI), serum glucose and LDL cholesterol (LDL-c) are associated with maximal cIMT values in low-risk individuals (no hypertension, diabetes, dyslipidemia or prior CV disease, no CV medications, no current or past smoking and a BMI &lt; 30 kg/m 2 ). Methods: We used data from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) baseline. ELSA-Brasil is a multicenter cohort of 15,105 civil servants aged 35-74 years in six Brazilian cities. Baseline assessment included cIMT measurements in both common carotid arteries. SBP, BMI, serum glucose and LDL-c values were standardized. We used multiple linear regression models to study the association of SBP, BMI, serum glucose and LDL-c with maximal cIMT (in mm). Results: We analyzed 1,569 ELSA-Brasil low-risk participants with complete cIMT data. There were 1,024 (65.3%) women and 924 (58.9%) of White race. Mean ± standard deviation (SD) for continuous variables were: age 46.1 ± 7.7 years; SBP 111.2 ± 10.8 mmHg; BMI 24.0 ± 2.9 kg/m 2 ; serum glucose 99.7 ± 7.8 mg/dl; LDL-c 105.6 ± 17.1 mg/dl and maximal cIMT 0.700 ± 0.136 mm. The table shows the beta-coefficients associated to one standard deviation increase in SBP, BMI, serum glucose and LDL-c. Conclusions: Even in a low-risk subsample, excluding individuals with hypertension, dyslipidemia or obesity, SBP, BMI and LDL-c were positively associated with higher maximal cIMT. This probably reflects a continuum of risk for atherosclerotic disease mediated by these measurements that do not evanesce with the exclusion of subjects who fulfill current diagnostic criteria for these conditions.
POPLITEAL ANEURYSM DUE TO SYPHILIS: REPORT OF A CASE
Authors: G B SILVER, J W KAHN
Journal: Annals of Internal Medicine (1952)

Case Reports1 March 1952POPLITEAL ANEURYSM DUE TO SYPHILIS: REPORT OF A CASEGERSHON B. SILVER, M.D., JACOB W. KAHN, M.D.GERSHON B. SILVER, M.D.Search for more papers by this author, JACOB W. KAHN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-36-3-888 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAlthough aneurysms of the popliteal artery are not too frequently seen, this vessel is the most common site for peripheral aneurysm formation. The chief cause of aneurysm of the vessels of the lower extremity is arteriosclerosis; Allen, Barker and Hines,1 in their textbook, state that this is indeed almost the only cause in individuals over 60. They also note less common causes, such as mycotic arteritis, necrotizing arteritis and trauma. They state that syphilis as a cause of aneurysm in the lower extremity is rare.The segment of the popliteal artery which is at the level of the femoral condyles...Bibliography1. AllenBarkerHines EVNWEH: Peripheral vascular diseases, 1946, W. B. Saunders Co., Philadelphia, p. 513. Google Scholar2. LuckeRea BMH: Studies on aneurysm. I. General statistical data on aneurysm, J. A. M. A. 77: 935-940 (Sept.) 1921. CrossrefGoogle Scholar3. Theis FV: Peripheral arterial aneurysm: diagnosis, prognosis and treatment, Internat. Clin. 2: 205-216 (June) 1940. Google Scholar4. Yater WM: Ruptured popliteal aneurysm: report of four cases, Am. Heart J. 18: 471-482 (Oct.) 1939. CrossrefGoogle Scholar5. WellsCoburnWalker AHCEMA: Popliteal aneurysm with report of case, J. A. M. A. 106: 1264-1266 (April 11) 1936. CrossrefGoogle Scholar6. Harley HR: Popliteal aneurysm, Guy's Hosp. Rep. 90: 255-295, 1940-1941. Google Scholar7. Matas R: Keen's Surgery, 1912, W. B. Saunders Co., Philadelphia, Vol. V, p. 334. Google Scholar8. Barker NW: Spontaneous false aneurysm of popliteal artery: arteriography, treatment, pathologic studies, report of case, M. Clin. North America 18: 613-622 (Sept.) 1934. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication March 24, 1950.From the Medical Service of Dr. E. L. Shlevin, Jewish Hospital, Brooklyn, New York. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byMiscellaneousPathologische Anatomie der SyphilisFurther Progress in Venereology 1 March 1952Volume 36, Issue 3Page: 888-896KeywordsAneurysmsArteriesFemoral arteriesMedical servicesSyphilis ePublished: 1 December 2008 Issue Published: 1 March 1952 PDF downloadLoading ...